RELIEF THERAPEUTICS Holding SA announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022. Paolo will continue his responsibilities as CEO of APR Applied Pharma Research SA ("APR") and as a member of Relief's Board of Directors. Since the acquisition of APR by Relief in June 2021, Mr. Galfetti has served as President of Relief Europe.

He joined APR in 1995 as head of licensing and business development and was appointed its Chief Executive Officer in 2002. Under his leadership, APR brought its PKU GOLIKE® family of products onto the market and developed a rich pipeline of product candidates. Earlier in his career, Mr. Galfetti was a founding partner, Chief Executive Officer, and board member of the Institute for Pharmacokinetic and Analytical Studies AG (IPAS), Chief Executive Officer, and board member of Farma Resa s.r.l. and a member of several Pharma licensing groups.

He is a Chartered Financial Analyst and holds a bachelor's degree in economics from the Commercial University Bocconi, Milan, Italy.